Invesco’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$93.5M Buy
2,429,629
+1,843,864
+315% +$68.1M 0.01% 856
2025
Q4
$20.8M Buy
585,765
+213,495
+57% +$6M ﹤0.01% 1447
2025
Q3
$5.35M Buy
372,270
+259,210
+229% +$3.07M ﹤0.01% 2199
2025
Q2
$812K Buy
113,060
+44,317
+64% +$246K ﹤0.01% 2938
2025
Q1
$412K Buy
68,743
+30,102
+78% +$236K ﹤0.01% 3230
2024
Q4
$301K Sell
38,641
-455,437
-92% -$4.54M ﹤0.01% 3414
2024
Q3
$5.34M Buy
494,078
+330,112
+201% +$3.21M ﹤0.01% 2183
2024
Q2
$1.38M Buy
163,966
+127,124
+345% +$964K ﹤0.01% 2780
2024
Q1
$248K Buy
36,842
+2,102
+6% +$13K ﹤0.01% 3580
2023
Q4
$204K Buy
34,740
+2,066
+6% +$15.8K ﹤0.01% 3564
2023
Q3
$319K Buy
32,674
+1,363
+4% +$16.2K ﹤0.01% 3430
2023
Q2
$371K Buy
31,311
+3,697
+13% +$42.4K ﹤0.01% 3405
2023
Q1
$298K Buy
27,614
+9,999
+57% +$128K ﹤0.01% 3504
2022
Q4
$204K Sell
17,615
-439,868
-96% -$5.45M ﹤0.01% 3680
2022
Q3
$6.83M Sell
457,483
-436,109
-49% -$5.98M ﹤0.01% 2033
2022
Q2
$8.06M Buy
893,592
+881,334
+7,190% +$6.02M ﹤0.01% 1988
2022
Q1
$92K Buy
12,258
+459
+4% +$3.2K ﹤0.01% 3873
2021
Q4
$102K Sell
11,799
-336
-3% -$2.92K ﹤0.01% 3900
2021
Q3
$102K Sell
12,135
-717,711
-98% -$5.5M ﹤0.01% 3939
2021
Q2
$5.92M Buy
729,846
+26,762
+4% +$226K ﹤0.01% 2360
2021
Q1
$6.17M Buy
703,084
+3,084
+0.4% +$29.7K ﹤0.01% 2266
2020
Q4
$7.86M Buy
+700,000
New +$7.69M ﹤0.01% 1933

Other funds holding COGT

Invesco's COGT Position: Q1 2026 in Review

Invesco increased its Cogent Biosciences (COGT) stake by 315% in Q1 2026, buying an estimated $68.1M and bringing the position to 2,429,629 shares worth $93.5M. The position accounts for 0.01% of the portfolio, ranked #856.

Invesco first reported a position in COGT in Q4 2020 and has held it in 22 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Invesco held 2,429,629 shares of Cogent Biosciences worth $93.5M as of Q1 2026.
  • Invesco bought 1,843,864 Cogent Biosciences shares in Q1 2026, an estimated $68.1M.
  • Cogent Biosciences made up 0.01% of Invesco's portfolio in Q1 2026, its #856 holding.
  • Invesco first reported a position in Cogent Biosciences in Q4 2020 and has held it in 22 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.